<?xml version="1.0" encoding="UTF-8"?>
<ref id="B31-pharmaceutics-11-00231" class="ref">
 <label class="label">31.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Joseph</surname>
    <given-names class="given-names">E.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Reddi</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Rinwa</surname>
    <given-names class="given-names">V.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Balwani</surname>
    <given-names class="given-names">G.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Saha</surname>
    <given-names class="given-names">R.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Design and in Vivo Evaluation of Solid Lipid Nanoparticulate Systems of Olanzapine for Acute Phase Schizophrenia Treatment: Investigations on Antipsychotic Potential and Adverse Effects</article-title>
  <source class="source">Eur. J. Pharm. Sci.</source>
  <year class="year">2017</year>
  <volume class="volume">104</volume>
  <fpage class="fpage">315</fpage>
  <lpage class="lpage">325</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.1016/j.ejps.2017.03.050</pub-id>
  <pub-id pub-id-type="pmid" class="pub-id">28408348</pub-id>
 </element-citation>
</ref>
